8th Jul 2026 01:17
Futura Medical PLC - Guildford, England-based pharmaceutical company - Disputes the European Patent Office's decision to revoke Futura's MED3000 patent. "The company disagrees with the Opposition Division's decision, which it believes does not appropriately reflect fundamental principles of clinical research and development, and therefore intends to appeal the decision to the EPO Technical Board of Appeal," says the company. MED3000 is a topical erectile dysfunction treatment, sold under the brand name Eroxon. Futura notes that the patent protection remains in force while the appeal is pending. Furthermore, the EPO's decision does not directly affect Futura's other granted or pending patents, says the company.
Current stock price: 0.50 pence, closed down 9.8% in London
12-month change: down 94%
By John Robaina, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Futura Medical